Evidence map›Paper›PMID 25081748›Full record

ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2015

Histopathologic findings associated with APOL1 risk variants in chronic kidney disease.

Christopher P Larsen, Marjorie L Beggs, Mohammad Saeed, Josephine M Ambruzs, L Nicholas Cossey, Nidia C Messias, Patrick D Walker, Barry I Freedman

Open access · bronzeAbstract read
In one paragraph

Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Genetic kidney disease in adults-the pathologists' perspective.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Collapsing Glomerulopathy.Advances in kidney disease and health · 2024
    Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Clinical journal of the American Society of Nephrology : CJASN · 2021
    Article
  17. Article
  18. Lessons From APOL1 Animal Models.Frontiers in medicine · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christopher P LarsenNephropath, Little Rock, AR, USA.
Marjorie L BeggsNephropath, Little Rock, AR, USA.
Mohammad SaeedNephropath, Little Rock, AR, USA.
Josephine M AmbruzsNephropath, Little Rock, AR, USA.
L Nicholas CosseyNephropath, Little Rock, AR, USA.
Nidia C MessiasNephropath, Little Rock, AR, USA.
Patrick D WalkerNephropath, Little Rock, AR, USA.
Barry I FreedmanInternal Medicine-Nephrology, Wake Forest School of Medicine, Winston-Salem, NC, USA.
Arkana Laboratories · USWake Forest University · US

Funding

Genetic Analysis of African American Hypertensive End-Stage Renal DiseaseR01DK070941 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FREEDMAN, BARRY IRA · 2006 to 2015
$4.7M
Natural History of MYH9-Associated NephropathyR01DK084149 · NIDDK · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI FREEDMAN, BARRY IRA · 2009 to 2012
$2.3M
NIDDK NIH HHS DK084149NIDDK NIH HHS R01 DK070941NIDDK NIH HHS R01 DK084149
6 · The paper itself

Abstract

The effects of nephropathy risk variants in the apolipoprotein L1 gene (APOL1) on renal histopathology in African Americans with arterionephrosclerosis or putative 'hypertension-associated' nephropathy are unknown. APOL1 genotype-phenotype correlations were performed in a blinded manner from renal biopsies in 196 self-reported African Americans with arterionephrosclerosis on kidney biopsy at a large national nephropathology practice. Subjects had chronic kidney disease without nephrotic syndrome. A discovery analysis compared histopathologic changes in the glomerular and tubulointerstitial compartments in 58 subjects with 2 versus 56 subjects with 0 APOL1 risk variants. Validation was performed in biopsies from 82 additional subjects with 0, 1, and 2 risk variants. Two risk variant versus zero risk variant group genotype associations and subphenotypes were assessed by χ(2) analyses. ANOVA compared means of continuous variables. In discovery analyses, significantly less obsolescent glomerulosclerosis, more (solidified and disappearing) glomerulosclerosis, more thyroidization-type tubular atrophy, and more microcystic tubular dilatation were seen in patients with two versus zero APOL1 risk alleles. Greater degrees of arteriosclerosis were present in those with zero risk alleles. Segmental glomerulosclerosis did not differ significantly between groups. Presence of two of the following discriminatory histopathologic findings from discovery, that is, <50% obsolescent glomerulosclerosis, thyroidization-type tubular atrophy, and microcystic tubular dilatation, was specific for the presence of two APOL1 risk alleles in the validation phase. African Americans with arterionephrosclerosis who possess two APOL1 risk variants more often lack obsolescent glomerulosclerosis and have greater degrees of (solidified and disappearing) glomerulosclerosis, thyroidization-type tubular atrophy, and microcystic tubular dilation than patients with fewer than two risk variants. These findings support involvement of multiple cell types in subnephrotic forms of APOL1-associated nephropathy, particularly renal tubule cells with resultant tubulointerstitial disease.

Indexed as

Apolipoprotein L1ApolipoproteinsBlack or African AmericanGenetic Predisposition to DiseaseGenotypeHumansLipoproteins, HDLPolymorphism, Single NucleotideRenal Insufficiency, ChronicAPOL1 protein, humanApolipoprotein L1ApolipoproteinsLipoproteins, HDL

Identifiers

PMID25081748
PMCPMC11163378
OpenAlexW2018208644

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.